Litcius/Paper detail

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial

Jian Zhou, Li Bai, Jia Luo, Yuxian Bai, Yaozhen Pan, Xinrong Yang, Yufeng Gao, Rongshu Shi, Wenhua Zhang, Jinfang Zheng, Xiangdong Hua, Aibing Xu, Sheng Hu, Feng Zhang, Xiao‐Jun Yang, Mingxu Da, Rui Wang, Jie Ma, Weidong Jia, Dongmei Quan, Chuang Peng, Wei Yang, Guowen Yin, Yue Qi, Guifang Zhang, Xilin Du, Xiaorong Mao, Zhiqiang Meng, Shunchang Jiao, Jia Fan

2025The Lancet Oncology41 citationsDOI

Topics & Concepts

Hepatocellular carcinomaSorafenibApolloMedicinePhase (matter)Internal medicineOncologyLine (geometry)PhysicsBiologyZoologyGeometryMathematicsQuantum mechanicsLung Cancer Research StudiesHepatocellular Carcinoma Treatment and PrognosisPeptidase Inhibition and Analysis